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Objective: To evaluate the efﬁcacy of deferiprone (DFP), 1-(N-acetyl-6-aminohexyl)-3-
hydroxy-2-methylpyridin-4-one (CM1) or green tea extract (GTE) in enhancing expres-
sion of hepatic hepcidin1 (Hamp1) mRNA and relieving iron overload in b-globin
knockout thalassemic mice.
Methods: The b-globin knockout thalassemic mice were fed with a ferrocene-
supplemented diet for 2 months and oral administration of deionized water, DFP
(50 mg/kg), CM1 (50 mg/kg), GTE (50 mg epigallocatechin 3-gallate equivalent/kg),
GTE along with DFP (50 mg/kg), and GTE along with CM1 (50 mg/kg) every day for 3
months. Levels of hepatic Hamp1 mRNA, plasma non-transferrin bound iron, plasma
alanine aminotransferase activity and tissue iron content were determined.
Results: All chelation treatments could reduce plasma non-transferrin bound iron con-
centrations. Additionally, hepatic Hamp1 mRNA expression was signiﬁcantly up-
regulated in the mice in a GTE + DFP combined treatment, correlating with a decrease
in the plasma alanine aminotransferase activity and tissue iron deposition.
Conclusions: The GTE + DFP treatment could ameliorate iron overload and liver
oxidative damage in non-transfusion dependent b-thalassemic mice, by chelating toxic
iron in plasma and tissues, and increasing hepcidin expression to inhibit duodenal iron
absorption and iron release from hepatocytes and macrophages in the spleen. There is
probably an advantage in giving GTE with DFP when treating patients with iron
overload.1. Introduction
Secondary iron overload in b-thalassemia patients is caused
by multiple blood transfusions and an increase of duodenal ironabsorption [1]. Apparently, toxic forms of iron known as non-
transferrin bound iron (NTBI), labile plasma iron and labile
iron pools (LIP) are detectable in these patients [2,3]. Effective
iron chelators are required to remove this iron to prevent
oxidative damage in the vital organs, particularly the heart and
liver. Nowadays, deferoxamine (DFO), deferiprone (DFP) and
deferasirox (DFX) are the iron chelators which are usually
used for the treatment of b-thalassemia patients with iron
overload; however, they do produce adverse effects [4]. 1-(N-
Acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1)
has been synthesized and proposed as a new bidentate iron
chelator whose chelating property and toxicity have so far been
investigated in vitro and in animals [5–7]. Green tea extractan open access article under the CC BY-NC-ND
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natural iron chelator both in vitro and in vivo [8–10].
Furthermore, iron chelators have been reported to increase
hepatic hepcidin expression [11,12]. Importantly, increased
hepcidin expression reduces iron overload and improves
anemia effectively [13,14].
Hepcidin, a hepatic 25-amino acid peptide hormone, is syn-
thesized and released into the blood circulation to regulate
systemic iron metabolism [15,16]. It inhibits iron ﬂux from
enterocytes, hepatocytes and macrophages to the blood stream
by binding to the iron-exporter ferroportin causing its internal-
ization and degradation [17,18]. The regulations result in a
retention of iron within the cells and a reduction of iron in the
plasma [19–21]. Recently, NTBI and hepcidin have been
proposed to be novel reliable markers for iron metabolism,
especially, iron overload condition [2,22,23]. Urinary and serum
hepcidin levels are decreased in b-thalassemia, which
exacerbates the condition leading to further iron overload [24].
Expression of hepcidin in patients with iron overload such as
b-thalassemia and myelodysplatic syndromes may be
suppressed by the growth differentiation factor 15, the twisted
gastrulation factor 1, the bone morphogenetic protein-binding
endothelial cell precursor-derived regulator and/or the eryth-
roferrone [2,25–28]. Nonetheless, the mechanism of hepcidin
regulation under these conditions is still unclear. In the present
study, we investigated the expression and beneﬁts of hepcidin
in iron-loaded b-globin knockout (BKO) thalassemic mice
treated with single and combined iron chelators. Hopefully, iron
chelators would lead to a negative iron balance in the body by
enhancing hepcidin expression, resulting in lowering duodenal
iron absorption and release of the iron from the liver and mac-
rophages in the spleen.2. Materials and methods
2.1. Chemicals and reagents
3-(2-Pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p0-disulfonic acid
monosodium salt hydrate (ferrozine), bis-(h5-cyclopentadienyl)-
iron (ferrocene), ferrous ammonium sulfate, 3-[N-morpholino]
propanesulfonic acid, nitrolotriacetic acid trisodium salt (NTA),
sodium acetate trihydrate, sodium dodecylsulphate, thioglycolic
acid and trichloroacetic acid were purchased from Sigma–
Aldrich Chemicals Co. Ltd., St. Louis, MO, USA. TRIzol re-
agent was purchased from Invitrogen Company, UK. RNA
isolation kit (Illustra RNAspin mini RNA isolation kit) was
purchased from GE Healthcare Company, UK. High capacity
cDNA reverse transcription kit was purchased from Applied
Biosystems Company, UK. The EXPRESS SYBR® GreenER™
qPCR Supermix universal kit was obtained from Invitrogen
Company, UK. Alanine aminotransferase (ALT) assay kit
was purchased from Biotech Co. Ltd., Thailand. Acetonitrile
[high performance liquid chromatography (HPLC) grade,
density = 0.782 g/cm3] was purchased from BDH, UK.
2.2. Iron chelators
DFP was kindly donated by the Government Pharmaceutical
Organization of Thailand. CM1 was synthesized by Dr. Kanjana
Pangjit, Ubon Ratchathani University, Thailand [5]. 1-Methyl-2-
propyl-3-hydroxypyridine-4-one (CP22) was kindly donated byProfessor Robert C. Hider, Institute of Pharmaceutical Science,
King's College London, United Kingdom.
2.3. GTE
Fresh tea (Camellia sinensis) leaves were harvested from a
local tea plantation in Chiang Mai, Thailand and immediately
dried in a microwave cabinet [8]. Hot water crude extract of
green tea was prepared and epigallocatechin 3-gallate (EGCG)
content was determined by using HPLC method [9,10]. The GTE
product containing 24% (w/w) EGCG was kept in the dark
at −20 C until studied.
2.4. Animals
Male and female C57/BL6 mice of wild type (WT, mub+/+),
aged 2–3 months old and weighed 20–25 g, and heterozygous
BKO (mubth−3/+) mice, were bred and supplied by the Thalas-
semia Research Center, Institute of Molecular Bioscience,
Mahidol University, Salaya Campus, Thailand [29,30]. The
experimental protocol was conducted with the approval of the
Animal Ethical Committee of Medical Faculty, Chiang Mai
University, Thailand (Reference No. 42/2556). WT and BKO
mice (n = 10; 5 in each gender) fed with a CP 082 normal
chow diet (N diet) (Perfect Companion Group Co. Ltd.,
Samuthprakarn, Thailand) were observed as the normal diet
control. For iron loading, six groups of BKO mice (n = 10; 5
in each gender) were fed with a 0.2% (w/w) ferrocene-
supplemented diet (Fe diet) for 2 months (Day 0–60) [31]. On
the 60th day, tail vein blood samples were collected before the
chelation treatments for analysis of plasma NTBI
concentrations and ALT activity. Afterwards, deionized water
(DI), DFP (50 mg/kg), CM1 (50 mg/kg), GTE (50 mg EGCG
equivalent/kg), GTE (50 mg EGCG equivalent/kg) together
with DFP (50 mg/kg), and the GTE (50 mg EGCG equivalent/
kg) together with CM1 (50 mg/kg) were orally administered
by using a gavage needle to the mice every day for 3 months
(Day 61–150) [10]. On the 150th day, all mice were sacriﬁced
and their blood was collected through cardiac puncture into
Na-heparin tubes for analysis of plasma NTBI concentrations
and ALT activity. The liver, spleen and duodenum were
collected, weighed and used for evaluation of the tissue iron
by using histochemical Perl's Prussian blue staining technique
and ferrozine colorimetric method. Organ weight index (OWI)
was calculated with the following formula:
OWI (%) = organ weight (g) × 100/body weight (g)
2.5. Quantiﬁcation of hepatic hepcidin1 (Hamp1) mRNA
RNA was extracted from 100 mg of mouse liver by using
TRIzol reagent, and the genomic DNA was removed from the
RNA samples by using the RNA isolation kit according to the
manufacturer's protocol. A total of 1 mg of RNA was reversely
transcribed into cDNA by using a high capacity cDNA reverse
transcription kit. Levels of Hamp1 mRNA in the liver were
quantiﬁed by using the quantitative real-time PCR (qPCR) with
DDCT method [32]. The housekeeping RNA b-actin (Actb) was
used as an endogenous control to normalize the cDNA samples
for relative quantitation. The qPCR reaction of cDNA was
performed by using the EXPRESS SYBR® GreenER™ qPCR
Table 1
OWI of WT and BKO mice (n = 10, 5 in each gender) fed with N diet or
Fe diet along with chelation treatments for 90 days. %.
Mice/treatment OWI
Liver Spleen
WT-N diet/DI 4.73 ± 0.50 0.33 ± 0.14
BKO-N diet/DI 5.03 ± 0.61 1.60 ± 0.40#
BKO-Fe diet/DI 10.00 ± 0.93* 2.12 ± 0.57*
BKO-Fe diet/DFP 9.72 ± 0.91 2.05 ± 0.35
BKO-Fe diet/CM1 10.06 ± 0.74 2.24 ± 0.40
BKO-Fe diet/GTE 9.73 ± 0.40 2.21 ± 0.36
BKO-Fe diet/GTE + DFP 9.77 ± 0.67 2.15 ± 0.23
BKO-Fe diet/GTE + CM1 9.54 ± 0.95 2.11 ± 0.53
#: P < 0.05 when compared with the WT-N diet/DI group; *: P < 0.05
when compared with the BKO-N diet/DI group.
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(Applied Biosystems, UK). The primer sequences used in qPCR
were presented as follows: mHamp1 forward: CCTGAGCAG-
CACCACCTATC, mHamp1 reverse: TGCAACAGATACCA-
CACTGGG, mActb forward: GGTCCACACCCGCCAC, and
mActb reverse: GTCCTTCTGACCCATTCCCA. Relative
mRNA expression in WT and BKO mice was acquired by
normalizing Hamp1 mRNA to Actb mRNA.
2.6. Plasma ALT activity assay
Plasma ALT activity of the mice on Day 60 and Day 150 was
examined by using ALT assay kit [33]. Difference in the ALT
activity was calculated.
2.7. Quantiﬁcation of plasma NTBI
Plasma NTBI concentrations of the mice on Day 60 and Day
150 were measured by using the HPLC method [34]. Brieﬂy,
plasma was incubated with a weak chelator NTA solution (at
a ﬁnal concentration of 80 mmol/L, pH 7.0) for 30 min at
room temperature to produce Fe3+-(NTA)2 complex.
Subsequently, the complex was ﬁltered through a membrane
(NanoSep®, 10-kDa cut-off, polysulfone type; Pall Life Sci-
ences, USA) and analyzed by using the non-metallic HPLC
system.
The Fe3+-(NTA)2 representing NTBI was fractionated on a
glass analytical column (ChromSep-ODS1, 100 mm × 3 mm,
5 mm particle size) and eluted at a ﬂow rate of 1 mL/min with a
mobile phase solvent containing 3 mmol/L CP22 in 19%
acetonitrile buffered with 5 mmol/L 3-[N-morpholino]propane-
sulfonic acid (pH 7.0) to generate a Fe3+-(CP22)3 product. El-
uents were monitored and detected at 450 nm with a ﬂow cell
detector (SpecMonitor2300; LDC Milton–Roy Inc., USA). Data
analysis was manipulated by BDS software (BarSpec Ltd.,
Israel). NTBI concentrations were represented by the Fe3+-
(CP22)3, while the peak height was determined from a standard
curve which was constructed from 0 to 16 mmol/L Fe3+-(NTA)2
in 80 mmol/L NTA. The difference in the NTBI concentrations
was calculated.
2.8. Histochemical examination of tissue iron
Liver, spleen and duodenum tissues were ﬁxed in 10%
neutralized formalin. Fixed tissue sections were dehydrated with
a gradual series of ethanol, embedded in parafﬁn, sectioned, and
stained with potassium ferrocyanide solution (known as Perl's
supravital dye) by using the standard protocol. The stained slides
were analyzed under a light microscope by an expert pathologist
and photographed with a digital camera.
2.9. Determination of tissue iron content (TIC)
TIC was measured by the ferrozine colorimetric method [35].
The liver, spleen and duodenum were dried at 120 C overnight
in a hot air oven. The dried organs were weighed and
homogenized in 0.5% (w/v) sodium dodecylsulphate solution.
The homogenate was added to the protein precipitating agent
(1 mol/L HCl/10% trichloroacetic acid solution), mixed
vigorously, and heated at 95 C for 1 h. After cooled down
to room temperature, the protein-precipitated solution wascentrifuged at 12000 r/min for 10 min. Iron in the supernatant
was then allowed to react with the chromogenic solution con-
taining 0.508 mmol/L ferrozine, 1.5 mol/L sodium acetate and
1.5% (v/v) thioglycolic acid for 30 min to generate the colored
product. The optical density of the product was measured
photometrically at 562 nm. Iron concentrations were deter-
mined from a calibration curve of 0–200 mmol/L ferrous
ammonium sulfate. The TIC was presented as mg/g organ dry
weight.
2.10. Statistical analysis
Data were analyzed by using the IBM SPSS Statistic 20
program and presented as mean ± SD. Statistical signiﬁcance
was determined by using One-way ANOVA test, and the results
with P < 0.05 were considered signiﬁcant.
3. Results
3.1. OWI
As shown in Table 1, the OWI value of the spleen from the
BKO-N diet mice was signiﬁcantly increased when compared
with the WT-N diet mice, and those of the liver and spleen from
the BKO-Fe diet mice were signiﬁcantly elevated when
compared with the BKO-N diet mice. However, the chelators
did not signiﬁcantly change any OWI values in the treated BKO-
Fe diet mice when compared with the untreated mice.
3.2. Hepatic Hamp1 mRNA expression
Hepatic Hamp1 mRNA expression was not found to be
signiﬁcantly different between genders in both WT and BKO
mice (Figure 1). Importantly, the hepatic Hamp1 mRNA levels
in the BKO-N diet mice were signiﬁcantly lower than those in
the WT-N diet mice, while the hepatic Hamp1 mRNA expres-
sion was increased in the BKO-Fe diet mice when compared
with the BKO-N diet mice (P < 0.05) (Figure 2). The hepatic
Hamp1 mRNA levels were increased signiﬁcantly in the BKO-
Fe diet/GTE + DFP group when compared with the BKO-Fe
diet/DI group. Nevertheless, there was no signiﬁcant change in
Hamp1 mRNA levels in the BKO-Fe diet/DFP, BKO-Fe diet/
CM1, BKO-Fe diet/GTE and BKO-Fe diet/GTE + CM1 groups
(Figure 2).
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Figure 1. qPCR of Hamp1 mRNA acquired from the livers of WT and
BKO mice (n = 10, 5 in each gender).
Values are expressed as mean ± SD for the fold change for the comparison
between both genders.
Table 2
Plasma ALT activity of WT and BKOmice (n = 10, 5 in each gender) fed
with the N diet or Fe diet along with chelation treatments for 90 days.
Mice/treatment Plasma ALT activity (IU/L)
Day 60 Day 150 Difference
WT-N diet/DI 13.65 ± 6.03 17.63 ± 3.27 3.98 ± 6.66
BKO-N diet/DI 14.27 ± 5.24 16.58 ± 5.29 2.31 ± 6.89
BKO-Fe diet/DI 38.02 ± 11.06* 54.76 ± 12.39* 16.74 ± 11.87*
BKO-Fe diet/DFP 35.91 ± 15.21 42.22 ± 11.95† 6.31 ± 16.27
BKO-Fe diet/CM1 38.29 ± 8.50 49.70 ± 10.03 11.40 ± 13.22
BKO-Fe diet/GTE 38.82 ± 10.30 50.31 ± 12.20 11.49 ± 9.00
BKO-Fe diet/
GTE + DFP
43.49 ± 17.55 44.65 ± 8.30† 1.16 ± 20.11†
BKO-Fe diet/
GTE + CM1
35.95 ± 11.46 56.80 ± 11.84 20.85 ± 19.11
Data are expressed as mean ± SD; *: P < 0.05 when compared with the
BKO-N diet/DI group; †: P < 0.05 when compared with the BKO-Fe
diet/DI group.
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The levels of plasma ALT activity in the BKO-N diet mice
were not signiﬁcantly different from those in the WT-N diet
mice (Table 2). However, the levels of plasma ALT activity
were increased signiﬁcantly in the BKO-Fe diet mice when
compared with the BKO-N diet mice, implying iron loaded-
oxidative liver damage in the BKO-Fe diet mice.
All single chelation treatments tended to lower the increased
plasma ALT activity levels with efﬁcacy in the order of
DFP > CM1, GTE when compared with the non-treatment
group (BKO-Fe diet/DI). Most importantly, the GTE + DFP
treatment (mean difference = 1.16 IU/L), but not the
GTE + CM1 treatment (mean difference = 20.85 IU/L), was
signiﬁcantly more effective than DFP treatment alone (mean
difference = 6.31 IU/L) as well as GTE treatment (mean
difference = 11.49 IU/L) and was the most effective in
decreasing plasma ALT activity when compared with the non-
treatment group.
Expectedly, plasma NTBI levels in the BKO-Fe diet mice
were much higher than those in the BKO-N diet mice (P < 0.05)WT-N 
diet/DI
Mice/Treatment
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BKO-Fe 
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Figure 2. Effect of the chelation treatments on hepatic Hamp1 mRNA
expression in the N diet and Fe diet-fed WT and BKO mice for 90 days
(n = 10, 5 in each gender).
Values are expressed as mean ± SD for the fold change for the comparison
with the BKO-Fe diet/DI group. #: P < 0.05 when compared with the WT-N
diet/DI group; *: P < 0.05 when compared with the BKO-N diet/DI group;
†: P < 0.05 when compared with the BKO-Fe diet/DI group.(Table 3). All treatments reduced the plasma NTBI levels
(P < 0.05); however, the GTE + DFP treatment seemed to show
the greatest effect.
Perl's Prussian blue staining results (Figure 3) revealed
numerous hemosiderin in sinusoidal macrophages, hepatocytes
and splenic macrophages in both red and white pulps of the
BKO-Fe diet mice. The duodenum also showed iron accumu-
lation with rare hemosiderin-laden macrophages in mucosa
when compared with the BKO-N diet mice. The WT-N diet mice
had no iron accumulation, and the BKO-N diet mice showed the
iron accumulation in the spleen with scattered hemosiderin-
laden macrophages in both red and white pulps. Only the
GTE + DFP combined treatment group showed less iron accu-
mulation in the liver and spleen, as compared with the BKO-Fe
diet group, but there was no iron accumulation in the duodenum.
Consistently, results of TIC demonstrated that the BKO-Fe diet
mice had signiﬁcant iron accumulation in the liver, spleen and
duodenum when compared with the BKO-N diet mice (Table 4).
All chelation treatments reduced the iron deposition slightly in
the liver and spleen, but not in the duodenum.
Obviously, the GTE + DFP combined treatment had the
greatest effect in decreasing the iron deposition signiﬁcantly in
the liver and spleen.Table 3
Plasma NTBI concentrations of WT and BKO mice (n = 10, 5 in each
gender) fed with the N diet or Fe diet along with chelation treatments for
90 days.
Mice/treatment Plasma NTBI concentrations (mmol/L)
Day 60 Day 150 Difference
WT-N diet/DI 1.20 ± 0.48 1.20 ± 0.26 0.00 ± 0.33
BKO-N diet/DI 1.00 ± 0.43 1.00 ± 0.35 0.00 ± 0.50
BKO-Fe diet/DI 4.14 ± 1.70* 14.71 ± 1.21* 10.57 ± 2.14*
BKO-Fe diet/DFP 6.48 ± 3.95† 9.17 ± 3.12† 2.69 ± 5.47†
BKO-Fe diet/CM1 5.51 ± 1.97 9.22 ± 3.19† 3.71 ± 3.09†
BKO-Fe diet/GTE 5.54 ± 1.98 9.02 ± 3.11† 3.47 ± 2.96†
BKO-Fe diet/
GTE + DFP
4.75 ± 0.90 6.77 ± 2.68† 2.02 ± 2.96†
BKO-Fe diet/
GTE + CM1
4.13 ± 0.90 7.91 ± 3.51† 3.78 ± 3.14†
Data are expressed as mean ± SD. *: P < 0.05 when compared with the
BKO-N diet/DI group; †: P < 0.05 when compared with the BKO-Fe
diet/DI group.
Mice/ Treatment Liver Spleen Duodenum
WT- N diet/ DI
BKO-N diet/ DI
BKO-Fe diet/ DI
BKO-Fe diet /DFP
BKO-Fe diet/ CM1
BKO-Fe diet/ GTE
BKO-Fe diet/ GTE + 
DFP
BKO-Fe diet/ GTE + 
CM1
Figure 3. Perl's Prussian blue stained tissues of the N diet or Fe diet-fed WT and BKO mice along with the chelation treatments for 90 days.
Table 4
TIC of WT and BKO mice (n = 10, 5 in each gender) fed with the N diet
or Fe diet along with chelation treatments for 90 days.
Mice/treatment TIC (mg/g dry weight)
Liver Spleen Duodenum
WT-N diet/DI 0.18 ± 0.10 1.86 ± 1.03 0.14 ± 0.05
BKO-N diet/DI 0.52 ± 0.25 3.06 ± 0.61 0.17 ± 0.09
BKO-Fe diet/DI 19.46 ± 1.62* 9.30 ± 1.98* 0.43 ± 0.09*
BKO-Fe diet/DFP 16.85 ± 4.22 9.07 ± 2.51 0.41 ± 0.13
BKO-Fe diet/CM1 17.10 ± 5.96 8.82 ± 3.22 0.41 ± 0.14
BKO-Fe diet/GTE 17.67 ± 3.41 8.30 ± 1.41 0.41 ± 0.07
BKO-Fe diet/
GTE + DFP
14.77 ± 2.16† 7.65 ± 1.02† 0.36 ± 0.10
BKO-Fe diet/
GTE + CM1
17.27 ± 5.37 8.39 ± 1.26 0.48 ± 0.13
Data are expressed as mean ± SD. *: P < 0.05 when compared with the
BKO-N diet/DI group; †: P < 0.05 when compared with the BKO-Fe
diet/DI group.4. Discussion
We used the BKO thalassemic mice loaded with ferrocene to
imitate iron overload in b-thalassemia intermediate patients. The
BKO mice displayed ineffective erythropoiesis, mild anemia and
splenic enlargement [29,36]. Plasma ALT activity, plasma NTBI
concentrations and liver iron accumulation in the BKO-N diet
mice were not much different from those in the WT-N diet mice,
whereas levels of these parameters were considerably increased
in the BKO-Fe diet mice. Some other groups have demonstrated
that mRNA expressions of iron-regulatory proteins such as
hepcidin, ferroportin, and transferrin receptors vary between the
genders of the mice [37,38]. However, we did not ﬁnd any
difference in hepatic Hamp1 mRNA expression between male
and female of WT and BKO mice in this study. That is in
accordance with the hepcidin expression in Huh7 cells grown
in the condition containing male and female b-thalassemic
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of the mice does not appear to affect basal hepcidin expression
in their livers.
We found that BKO mice had signiﬁcantly lower Hamp1
mRNA levels than WT mice, which was consistent with pre-
vious reports in b-thalassemic mice and humans [39,40].
Interestingly, the up-regulation of Hamp1 mRNA expression
in the BKO-Fe diet mice found in this study would reﬂect the
increase of their tissue iron stores or serum iron concentrations
in order to suppress duodenal iron absorption and iron release
from the liver and macrophages in the spleen. Gardenghi et al.
also reported that levels of hepcidin were increased while iron
concentrations in the organs were increased and hepcidin still
partially responded to iron overload in b-thalassemic mice [41].
The levels of iron-loading in this study may overcome the
effects of hepcidin suppressors, resulting in hepcidin up-
regulation. Controversially, iron levels might not increase
hepcidin expression in b-thalassemia with ineffective eryth-
ropoiesis according to high levels of hepcidin suppressors
(e.g., growth differentiation factor 15, twisted gastrulation
factor 1, bone morphogenetic protein-binding endothelial cell
precursor-derived regulator or erythroferrone), which do have
a greater inﬂuence on decreasing hepcidin levels [27,42,43].
However, the increased hepcidin levels in the GTE + DFP
treatment could not result from the iron-loading effect with
regard to the reduction of the plasma NTBI levels and iron
accumulation in the tissues when compared with the non-
treatment group.
Accordingly, GTE + DFP combined treatment was more
effective than the DFP treatment alone in diminishing iron
overloaded liver damage and consequently decreasing plasma
levels of ALT activity in the BKO-Fe diet mice. We expect that
green tea catechins may potentiate iron depletion in cooperation
with DFP chelator by shuttling the iron from the Fe3+-(DFP)3
complex. When DFP and DFO co-exist in plasma, DFP would
ﬁrstly shuttle intracellular iron and plasma NTBI and transfer
them to DFO to form a ferrioxamine, implying that DFP com-
mits to removing labile iron in the liver cells [44,45]. Similarly,
the GTE catechins (particularly EGCG) could enhance DFP
chelation by shuttling the iron from the iron-DFP complex to
form the iron-EGCG complex [9,10]. Signiﬁcantly, the
GTE + DFP combined treatment lowers levels of plasma ALT
activity and liver iron accumulation efﬁciently, suggesting that
green tea polyphenols would improve iron-induced dysfunc-
tion and injury of the livers in BKO-Fe diet mice. A current
study has supported that the combined chelation treatment
synergized mobilization of labile iron pools in Huh7 cells, in
which the DFX + DFP treatment was the most effective [45].
Though effect of green tea consumption on iron absorption is
not conclusive deﬁnitely, we believe that it will not affect our
study [46,47].
Consistently, green tea signiﬁcantly increased glutathione
peroxidase, catalase, quinine reductase and glutathione S-trans-
ferase activities in the liver and improved the liver function by
its anti-oxidative effect against hepatotoxicity [48–50]. Taken
together, this may explain the increased hepatic hepcidin
expression following the improvement of the liver functions.
In addition, DFX chelation treatment could decrease plasma
ALT levels in the patients with iron overload-associated liver
dysfunction, and elevate serum hepcidin level in iron-overloaded
patients with myelodysplastic syndrome [51]. Unexpectedly,
GTE + CM1 combined treatment neither induced hepcidinexpression nor reduced the plasma ALT activity. Since CM1
molecule is more lipophilic, but bigger than DFP, the
GTE + CM1 combined treatment may be less efﬁcient than
the GTE + DFP combined treatment in removing the iron via
the proposed iron-shuttling mechanism. In all likelihood as
mentioned above, we imply that the GTE + DFP combined
treatment is more effective than the GTE + CM1 combined
treatment and the single chelation treatments in the reduction of
plasma NTBI concentrations and iron accumulation in the liver
and spleen. Consequently, the GTE + DFP treatment could
relieve oxidative damage in the liver and enhance hepcidin
expression and secretion, and the latter will limit iron absorption
in the duodenum and iron release from hepatocytes and mac-
rophages in the spleen.
In conclusion, GTE + DFP combined treatment is the most
effective in increasing Hamp1 mRNA expression and reveals
beneﬁcial health effects by lowering plasma NTBI levels, tissue
iron deposit and liver oxidative damage in b-thalassemic mice
with iron overload. Efﬁcacy of GTE + DFP combined treatment
on hepcidin expression/secretion and changes of iron parameters
should be further investigated clinically in b-thalassemia pa-
tients with iron overload.
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